ChemoCentryx’s Avacopan Scores European Approval For ANCA-Associated Vasculitis
The European Union has approved ChemoCentryx Inc's (NASDAQ: CCXI) Tavneos (avacopan) for ANCA-associated vasculitis.
ChemoCentryx Q3 EPS $(0.32) Beats $(0.45) Estimate, Sales $17.74M Beat $13.48M Estimate
ChemoCentryx (NASDAQ:CCXI) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.45) by 28.89 percent. This is a 8.57 percent increase over losses of $(0.35) per share from the
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.
Earnings Preview For ChemoCentryx
ChemoCentryx (NASDAQ:CCXI) is set to give its latest quarterly earnings report on Tuesday, 2021-11-09. Here's what investors need to know before the announcement.
Analysts estimate that ChemoCentryx will likely report an Earnings Per Share (EPS) of $-0.45
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes.
PDUFA dates are key binary events for biotech stocks that can move the needle in a big way. These are the dates by which the Food and Drug Administration is required to announce its decision regarding approvability/non-approvability of drugs.
BZ Chart Of The Day: ChemoCentryx
There’s an old saying on Wall Street that "gaps refill." It's true and it may be about to happen to shares of ChemoCentryx, Inc. (NASDAQ: CCXI).
There’s a logical reason why this happens.
